First-Line Vascular Endothelial Growth Factor Inhibitors for Advanced Renal Cell Carcinoma and the Impact of New Agents Entering the Treatment Paradigm

BJU International - United Kingdom
doi 10.1111/bju.13954
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Wiley

Related search

Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma in Adults Following Prior Vascular Endothelial Growth Factor Targeted Therapy: Clinical Trial Evidence and Experience

Therapeutic Advances in Urology
Urology
2018English

Predicting Postoperative Recurrence of Renal Cell Carcinoma Using Serum Vascular Endothelial Growth Factor

Japanese Journal of Urology
Urology
2013English

Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2007English

M-Tor Inhibitors in the Treatment of Advanced Renal Cell Carcinoma

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2011English

Prognostic Significance of Serum Hepatocyte Growth Factor in Clear Cell Renal Cell Carcinoma: Comparison With Serum Vascular Endothelial Growth Factor

Journal of Medical Investigation
BiochemistryMedicineGeneticsMolecular Biology
2008English

Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

Future Oncology
MedicineCancer ResearchOncology
2019English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

Vascular Endothelial Growth Factor Inhibitors in the Treatment of Neovascular Age-Related Macular Degeneration

Vestnik Oftalmologii
MedicineOphthalmology
2017English

Optimal First‐line Treatment for Advanced Thymic Carcinoma

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy